Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin Article

Industry Collaboration International Collaboration

cited authors

  • Corbin, Karen D.; Dagogo-Jack, Samuel; Cannon, Christopher P.; Cherney, David Z. I.; Cosentino, Francesco; Frederich, Robert; Liu, Jie; Pong, Annpey; Lin, Jianxin; Cater, Nilo B.; Pratley, Richard E.

authors

Publication Date

  • December 26, 2022

webpage

published in

category

keywords

  • SGLT2 inhibitor
  • cardiovascular disease
  • fibrosis-4 score
  • hepatic steatosis index
  • type 2 diabetes mellitus

start page

  • 758

end page

  • 766

volume

  • 25

issue

  • 3